This phase I trial compares the effect of lutetium Lu 177 (177^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177^Lu-PSMA-617 alone in treating patients with prostate that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow and spread despite surgical or medical intervention to block androgen production (castration-resistant). 177^Lu-PSMA-617, a type of radioconjugate, binds to a protein called PSMA, which is found on some prostate tumor cells. It gives off radiation that may kill the tumor cells. Sipuleucel-T, a type of vaccine and a type of cellular adoptive immunotherapy, is made from immune system cells. The cells are treated with a protein that is made by combining a protein found on prostate tumor cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate tumor cells. Giving 177^Lu-PSMA-617 in combination with sipuleucel-T may be safe, tolerable, and/or effective compared to 177^Lu-PSMA-617 alone in treating patients with metastatic castration-resistant prostate cancer.

Start Date05 Mar 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06100705

/ RecruitingPhase 2IIT

A Single Arm Open-label, Phase II Study of Sipuleucel-T With Bipolar Androgen Therapy in Men With Metastatic Castration-resistant Prostate Cancer

This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate cancer (mCRPC).

Start Date20 Dec 2023

Sponsor / Collaborator

Yale University

[+1]

NCT05806814

/ RecruitingPhase 1IIT

Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

Start Date12 Nov 2023

Sponsor / Collaborator

University of Oklahoma

[+1]

100 Clinical Results associated with Sipuleucel-T (Dendreon Corporation)

100 Translational Medicine associated with Sipuleucel-T (Dendreon Corporation)

100 Patents (Medical) associated with Sipuleucel-T (Dendreon Corporation)

596

Literatures (Medical) associated with Sipuleucel-T (Dendreon Corporation)

01 Jun 2026·Health policy OPEN

Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States

Article

Author: Kaye, Deborah R ; Scales, Charles D ; George, Daniel J ; Lee, Hui-Jie ; Bundorf, M Kate

Background:

Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infusion center fees, labs, etc) are often unknown and could impact the effectiveness of price transparency tools. Objective: To examine total OOP payments on day of drug receipt ("full day", i.e. drug + drug administration fees) out-of-pocket (OOP) payments associated with six first-line treatments for metastatic castrate resistant prostate cancer and compare these with payments for drug alone and by insurance type.

Methods:

Using the IBM Marketscan databases, we identify male patients who initiated treatment with one of six focus drugs (docetaxel, abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223) used to treat mCRPC from 07/01/2013-06/30/2019. We calculated total OOP payments on day of drug receipt (full day OOP payments) by drug type for six first line treatments. We then used a two-part model to assess the association of first-line therapy with OOP payments for the four most frequently prescribed during the study time period.

Results:

We find that there is variation in the proportion of payments for drug alone relative to full day payments across first-line treatments. However, regression-adjusted mean full day OOP payments are not statistically different across first-line treatments for mCRPC for the four most frequently prescribed drugs. There are differences in the likelihood that an individual will incur any OOP payment by first-line treatment type and by health plan type.

Conclusion:

These analyses suggest that when accounting for additional services required on the day of drug receipt, the amount a patient pays to receive a medication for mCRPC can be very different from the OOP payment for the drug alone; these payments also vary by drug and health plan type. Therefore, price transparency for drug alone may not lead to reduced OOP payments for patients.

01 Dec 2025·Journal for ImmunoTherapy of Cancer

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer

Review

Author: Song, Wilbur ; McCoy, Sara ; Mathews, Parker ; Pachynski, Russell K ; Punia, Varnika ; Rawat, Kavita ; Saeed, Muhammad A

Clinical trials of immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) have largely been unsuccessful despite promising preclinical studies and proven efficacy in other solid tumors. These disappointing clinical outcomes have been attributed to an immunosuppressive tumor microenvironment, a relative lack of infiltrating immune effector cells, and tumor-related and host-related factors, which collectively render prostate cancer a relatively immunologically “cold” tumor. Sipuleucel-T (Provenge), an autologous cellular immunotherapy, induces an immune response targeted against prostatic acid phosphatase. It received approval from the US Food and Drug Administration in 2010, marking the first immunotherapy to show an overall survival benefit in patients with mCRPC in large phase III randomized trials. Unfortunately, subsequent immunotherapy-based strategies have been less efficacious in mCRPC relative to other tumor types. Given the use of sipuleucel-T as a standard of care backbone, there is emerging interest in combining it with other immunotherapies, hormonal therapies, or chemotherapies to improve its clinical efficacy. This review summarizes past experiences and current knowledge of combining sipuleucel-T with other treatments and explores future approaches to enhance such combinatorial strategies.

01 Nov 2025·European Urology Focus

Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies

Review

Author: Raval, Amit D ; Queen, Viji ; Freedland, Stephen J ; Quintero, Vanessa ; Korn, Matthew J

BACKGROUND AND OBJECTIVE:

Treatment options have evolved for metastatic castration-resistant prostate cancer (mCRPC). The aim of our study was to examine real-world (RW) treatment patterns and survival for individuals with mCRPC via a systematic literature review of RW observational studies.

METHODS:

Electronic databases (PubMed, Embase, and the Cochrane Library) and key conferences (2022-2025) were systematically searched for reports published between January 2015 and June 2025 on treatment patterns and RW overall survival (OS) in mCRPC.

KEY FINDINGS AND LIMITATIONS:

From 7727 articles retrieved, 45 studies met the inclusion criteria. Most studies were from the USA. Bone metastases were present in ≥80% and visceral metastases in ≤28% of cases at mCRPC diagnosis. Androgen receptor pathway inhibitors (ARPIs) were the first-line treatment most frequently used for mCRPC (≥50% in most studies). Chemotherapy was the second most common first-line mCRPC treatment and was more common in Europe and Oceania than in the USA. Use of radiopharmaceuticals, olaparib, and sipuleucel-T in first-line mCRPC was low in most studies (<10%). ARPI-to-ARPI from the first to the second line was the most common sequence in the US studies. Median RW OS was ≤34 mo from either mCRPC diagnosis or initiation of first-line mCRPC treatment in most studies.

CONCLUSIONS AND CLINICAL IMPLICATIONS:

The findings showed that ARPIs are the most frequent first- and second-line treatments in mCRPC, and back-to-back ARPI sequencing is also common practice, especially in the USA, despite the availability of therapies beyond ARPIs. The findings highlight the need to optimize treatment beyond systemic hormone therapy in this setting.

News (Medical) associated with Sipuleucel-T (Dendreon Corporation)

10 Apr 2025

·investors.sentibio.com

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from “bench to bedside” and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisory Board (“SAB”). Dr. Trager is a well-established biotechnology leader deeply versed in the development and application of cellular therapies for cancer. He brings to Senti Bio over 25 years of technical expertise, strategic execution and development of novel cellular and biologic therapies. In addition to his industry positions, he also serves as an advisor for the Shoreline Community College Immunotherapy Biohub and SPARK at Stanford. Over the course of his career, he has contributed to nearly 50 publications, abstracts and patents. “James brings a wealth of leadership experience and scientific expertise to our SAB, that we believe will be invaluable as we continue to advance the development of our potential best-in-class oncology programs. We look forward to leveraging his decorated career in research and product development moving forward,” says Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. “Senti Bio’s Logic Gating technology has demonstrated encouraging potential to address the central challenge in oncology which is to precisely distinguish cancer vs healthy cells and maximize therapeutic potential. Additionally, the data seen to date from the SENTI-202 program for AML has shown a lot of promise as a potential treatment option in this indication where there remains significant unmet medical need. I am excited to be joining the Senti Bio SAB and look forward to working closely with the team to advance this important technology and pipeline of product candidates,” added Dr. Trager. Dr. Trager formerly served as the Chief Scientific Officer of Nkarta Therapeutics where he led the development of multiple discovery assets through IND and the creation of a pipeline of CAR NK product opportunities. Prior to his role at Nkarta, Dr. Trager held a number of increasing roles and responsibilities at Dendreon Pharmaceuticals, Inc., most recently having served as Vice President of Research and Product Development, where he was responsible for product and biomarker development development activities, supporting the late stage development of sipuleucel-T through clinical study, approval, and commercialization. Prior to that, Dr. Trager served as a Senior Scientist at Geron Corporation, where he was part of the team that cloned human telomerase, and enabled the manufacture and clinical development of a telomerase inhibitor. Across his career, he managed and integrated the efforts of over 100 scientists, engineers and technicians contributing to the invention and development of multiple cell therapies. Dr. Trager holds a BA from St. John’s College in Santa Fe New Mexico and his Ph.D. in Molecular Biology and Biochemistry from the University of California at Berkeley. About Senti Bio Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, is currently enrolling patients in a Phase I clinical trial. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example Logic Gates that enable selective targeting of solid tumors. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships. Forward-Looking Statements This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the success of our future clinical development and ability to create shareholder value. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio’s dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio’s grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Investor Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 SNTI@jtcir.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/51b2998d-5e06-4e0c-90f4-5c75ab43f03e

Phase 1Executive ChangeGene TherapyCell Therapy

14 Mar 2025

·www.pharmaceutical-technology.com

Unsafe and unregulated cell therapies being sold in Europe

Dendritic cell therapies have shown promise in cancer treatment, but have not yet been approved by the EMA. Image credit: Shutterstock/ Juan Gaertner. The European Medicines Agency (EMA) has issued a warning about the dangers of unregulated advanced therapy medicinal products (ATMPs) being illegally offered to patients in Europe. ATMPs encompass a wide range of treatments including those that are based on cells, genes, or tissues. Advanced therapies have become a promising option in recent years to treat rare diseases and certain types of cancer. Whilst the EMA has approved multiple products for patient use, the agency said that individuals, companies, and clinics are also marketing unregulated ATMPs. There is little to no evidence these unregulated products work and can cause serious side effects, putting patients at risk. The EMA said that sellers exploit patient distress, selling treatments on websites or social media channels “as a last hope.” The EMA pointed to quality-related risks in the manufacturing process for unregulated ATMPs, which can lead to contamination, inconsistent product composition, and improper storage. A particular modality highlighted by the agency was dendritic cell therapies, a form of immunotherapy that has shown some promise in treating cancers. The therapy uses the patients’ own dendritic cells to initiate an immune response and attack cancer cells. Dendreon Pharmaceuticals used to make the only EMA-approved dendritic cell therapy called Provenge (sipuleucel-T), which received marketing authorisation in 2013. However, approval was withdrawn in May 2015 by Dendreon citing its poor commercial performance. The vaccine is still available in the US. “It is important that patients are only offered ATMPs, including dendritic cell therapies, that have been authorised or approved by a regulator,” the EMA said in a statement. “Authorities across the EU are working together to clamp down on those supplying unregulated ATMPs. The public are requested to report any suspicious cases to their national competent authorities,” the agency added. Murky landscape for dendritic cell therapies For ATMPs, there exists a grey zone between EMA-approved products and therapies regulated at the national level. There are various clinics in Germany that offer dendritic cell therapy, for example. Booking Health, a German medical tourism operator, connects cancer patients with clinics that charge up to €38,000 for the treatment, though costs can increase depending on further lab tests and required medication. On the company’s website, the company lists its laboratory being regulated by the EMEA, the Paul Ehrlich Institute, and local regional councils, but does not mention therapy-specific regulatory approvals. The EMEA and other drug regulatory bodies like the US Food and Drug Administration provide approvals or clearances to laboratories and ATMPs through different pathways, each with its own set of data requirements. IOZK, an immunological institution based in Cologne, Germany, claims it is the only laboratory in Europe to have received a manufacturing license to produce an individual vaccine – called IO-VAC – to combat cancer using dendritic cells. The EMA does not oversee IO-VAC’s use, though states that ATMPs can be given as part of a special exemption or clinical trial that is authorised at the national level. Germany is able to approve its own ATMPs through national regulatory pathways. IOZK says on its website: “We can already make this available to tumour patients today – even if it is not yet a standard of care.” The warning by the EMA is not the only instance in recent times that a health agency has had to clamp down on unregulated medicinal products. The World Health Organization (WHO) issued an alert in June last year relating to falsified batches of popular type 2 diabetes drug Ozempic (semaglutide). The agency said the unregulated products could have harmful effects on patient health. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

VaccineImmunotherapyCell Therapy

10 May 2024

·www.pharmaceutical-technology.com

WestGene wins FDA approval for mRNA vaccine to treat certain cancers

Chinese biotech WestGene announced an FDA approval for its mRNA therapeutic cancer vaccine. Credit: aslysun via Shutterstock. The US Food and Drug Administration (FDA) has approved an mRNA therapeutic cancer vaccine developed by China-based biotech WestGene. This decision makes the vaccine the world’s first approved mRNA therapeutic vaccine to treat Epstein Barr (EB)-virus-related cancers. The approval was based on results from investigator-initiated trials that evaluated the vaccine in patients with nasopharyngeal carcinoma (NPC) and natural killer T cell lymphoma. EB virus is a part of the herpesvirus family and spreads primarily through bodily fluids. The illness infects more than 90% of the global adult population but does not always lead to cancer, as detailed by Cancer Research UK. The virus has been linked with NPC, gastric cancer, lung cancer and other diseases. In a 10 May press release, WestGene highlighted liver cancer, oesophageal cancer, breast cancer and the aforementioned diseases as potential future indications for the vaccine. The Chinese company has a pipeline that includes four infectious disease vaccines, seven anti-tumour immunotherapies, and three gene editing treatments amongst other therapies. See Also: Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension Four ways the vaccine rush will define infectious disease trends for CROs in 2024 In 2010, the FDA approved Dendreon Pharmaceutical’s prostate cancer prophylactic Provenge (sipuleucel-T) as the first marketed therapeutic cancer vaccine. Since its approval, other therapeutic cancer vaccines have entered the US market, with eight being available in the US, according to GlobalData. GlobalData is the parent company of Pharmaceutical Technology. In 2021, Pfizer and BioNTech gained the first-ever FDA approval for an mRNA vaccine with Comirnaty (BNT162b2) as a preventative measure against Covid-19. Since this milestone, several preventive and therapeutic mRNA vaccines have been in development for a wide range of conditions. Some pharmaceutical companies are using the mRNA approach to develop vaccines for other infectious diseases such as respiratory syncytial virus (RSV), Influenza A, Influenza B and cytomegalovirus while companies, including Moderna , Curevac , and Cartesian Therapeutics, are developing therapeutic mRNA vaccines for treating different cancers.

VaccineDrug ApprovalImmunotherapymRNA

100 Deals associated with Sipuleucel-T (Dendreon Corporation)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sipuleucel-T (Dendreon Corporation)	L03AX17	DB06688

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	United States	Bausch Health Americas, Inc.	02 May 2010
Metastatic castration-resistant prostate cancer	United States	Dendreon Pharmaceuticals, Inc.	29 Apr 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of prostate	Phase 3	United States	Dendreon Corp.	18 Oct 2018
Castration-Resistant Prostatic Cancer	Phase 3	United States	Dendreon Corp.	01 Jul 2003
Castration-Resistant Prostatic Cancer	Phase 3	Canada	Dendreon Corp.	01 Jul 2003
Metastatic Prostate Carcinoma	Phase 3	United States	Dendreon Corp.	01 Jul 2003
Metastatic Prostate Carcinoma	Phase 3	Canada	Dendreon Corp.	01 Jul 2003
Non-metastatic prostate cancer	Phase 3	United States	Dendreon Corp.	01 Oct 2001
Advanced Prostate Carcinoma	Phase 2	Austria	Dendreon Corp.	26 Jan 2012
Localized Prostate Carcinoma	Phase 2	United States	Dendreon Corp.	01 Jul 2008
Bone metastases	Clinical	United States	Dendreon Corp.	03 Jul 2013
Recurrent Prostate Carcinoma	Clinical	United States	Dendreon Corp.	03 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SoNaR for Prostate Cancer (ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer prostate-specific antigen	-	Sipuleucel-T treated cohort	dltozefjcr(sfbtllqlbc) = jtktfonctk edkhkfcsxc (vgqipwflcg )	Positive	30 May 2025
NCT01487863 \| NCT01981122 (STAMP and STRIDE Trials, Pubmed \| Clin Cancer Res)	Not Applicable	Metastatic castration-resistant prostate cancer	-	Sipuleucel-T + Abiraterone Acetate	pxvlgztals(kyqxdloygr) = significantly elevated vs baseline jybvrahega (raxtviyfsj )	-	14 Apr 2023
				Sipuleucel-T + Enzalutamide
NCT01818986 (CTgov)	Phase 2	Metastatic castration-resistant prostate cancer	20	Stereotactic Ablative Body Radiation+Sipuleucel-T	qzbiidatbo(iktowrfwaw) = popdeoytzg vlzgsdhzni (tsgrmqhgcx, ulvxxautbt - btbcqmqejb) View more	-	06 May 2022
NCT01306890 (PROCEED, Pubmed \| Prostate Cancer Prostatic Dis)	Not Applicable	Metastatic castration-resistant prostate cancer	1,902	Sipuleucel-T	cpgiiktgpy(dpturqbzte) = kqrhlpnxaj wclfpqqqif (aiwindyjja ) View more	Positive	10 Feb 2022
ASTRO2020	Phase 2	Metastatic castration-resistant prostate cancer	20	Sipuleucel-T and SAbR	rzhwfcvqkt(gavkylovyd) = auejzoccct lsyultwhpp (tioewevcss, 6.8 - 14.0) View more	Negative	01 Nov 2020
NCT01807065 (CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Metastatic castration-resistant prostate cancer \| Bone metastases ... View more	51	laboratory biomarker analysis+sipuleucel-T (Arm A (Sipuleucel-T))	dcyiwglgkd(qjvagpwmzd) = rjnoypfoif ejatirimhd (bhjncarixj, smttinmqfs - zynkuobqgy) View more	-	25 Aug 2020
				laboratory biomarker analysis+sipuleucel-T (Arm B (Radiation Therapy, Sipuleucel-T))	dcyiwglgkd(qjvagpwmzd) = uusfxvvgql ejatirimhd (bhjncarixj, pldzpiwdgj - ixulddvtaw) View more
ASCO2020	Not Applicable	Castration-Resistant Prostatic Cancer	-	sipuleucel-T (White patients)	bndnzfplmo(pdbyiwkdlq): HR = 0.69 (95% CI, 0.4 - 1.4), P-Value = 0.277	-	25 May 2020
				sipuleucel-T (Asian patients)
NCT02463799 (ASCO2020)	Phase 2	Metastatic castration-resistant prostate cancer	32	Sipuleucel-T	ujnvwexstd(rewdomqcxf) = fqpvkamnzd eqdalcoiub (eobvwwqeeo ) View more	Positive	25 May 2020
				Sipuleucel-T + Radium-223	ujnvwexstd(rewdomqcxf) = rnpbamkzoq eqdalcoiub (eobvwwqeeo ) View more
NCT01306890 (PROCEED, Pubmed \| Prostate Cancer Prostatic Dis)	Not Applicable	Castration-Resistant Prostatic Cancer \| Advanced Prostate Carcinoma	1,900	sipuleucel-T (African American men)	kmdmxxuufs(yiydfyfozj) = cxcedbhzan rqvdxemcmn (cxzjjbruek )	-	28 Feb 2020
				sipuleucel-T (Caucasian men)	kmdmxxuufs(yiydfyfozj) = fdbdqrhgas rqvdxemcmn (cxzjjbruek )
NCT02463799 (ASCO_GU2020)	Phase 2	Castration-Resistant Prostatic Cancer	32	Sipuleucel-T	bzpslruaxd(eynmzkfyss) = No safety concerns were observed with the combination xvafkdvagb (umbzixmzvj ) View more	Positive	19 Feb 2020
				Sipuleucel-T + Radium-223

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sipuleucel-T (Dendreon Corporation)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation